Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo

Donghong Zhang, Xina Xie, Yequn Chen, Bruce D. Hammock, Wei Kong, Yi Zhu

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Rationale: Hyperhomocysteinemia is a risk factor of atherogenesis. Soluble epoxide hydrolase (sEH) is a major enzyme that hydrolyzes epoxyeicosatrienoic acids and attenuates their cardiovascular protective effects. Whether homocysteine (Hcy) regulates sEH and the underlying mechanism remains elusive. Objective: To elucidate the mechanism by which Hcy regulates sEH expression and endothelial activation in vitro and in vivo. Methods and Results: Hcy treatment in cultured human endothelial cells dose-dependently and time-dependently upregulated sEH mRNA and protein. Hcy increased the expression of adhesion molecules, which was markedly reversed by inhibiting sEH activity. Hcy-induced sEH upregulation is associated with activation of activating transcription factor-6 (ATF6). Bioinformatics analysis revealed a putative ATF6-binding motif in the promoter region of the sEH gene, which was found at a methylation site. Site-directed mutagenesis and chromatin immunoprecipitation assays demonstrated that Hcy treatment or ATF6 overexpression promoted ATF6 binding to the promoter of sEH and increased its activity. Results of methylation-specific polymerase chain reaction revealed that the ATF6 binding site on the sEH promoter was partially methylated and was demethylated with Hcy. SiRNA knockdown of ATF6α or SP1 blocked and ATF6 overexpression and DNA methyltransferase inhibitor mimicked the effect of homocysteine on sEH upregulation. In vivo, immunofluorescence assay revealed elevated expression of sEH and adhesion molecules in the aortic intima of mice with mild hyperhomocysteinemia, which was attenuated by sEH deletion or inhibition. Conclusion: ATF6 activation and DNA demethylation may coordinately contribute to Hcy-induced sEH expression and endothelial activation. Inhibition of sEH may be a therapeutic approach for treating Hcy-induced cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)808-817
Number of pages10
JournalCirculation Research
Volume110
Issue number6
DOIs
StatePublished - Mar 16 2012

Fingerprint

Epoxide Hydrolases
Vascular Endothelium
Homocysteine
Activating Transcription Factor 6
Up-Regulation
Hyperhomocysteinemia
In Vitro Techniques
Methylation
Chromatin Immunoprecipitation
DNA
Methyltransferases
Site-Directed Mutagenesis
Computational Biology
Genetic Promoter Regions

Keywords

  • activating transcription factor 6
  • demethylation
  • endothelial cells
  • homocysteine
  • soluble epoxide hydrolase

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. / Zhang, Donghong; Xie, Xina; Chen, Yequn; Hammock, Bruce D.; Kong, Wei; Zhu, Yi.

In: Circulation Research, Vol. 110, No. 6, 16.03.2012, p. 808-817.

Research output: Contribution to journalArticle

Zhang, Donghong ; Xie, Xina ; Chen, Yequn ; Hammock, Bruce D. ; Kong, Wei ; Zhu, Yi. / Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. In: Circulation Research. 2012 ; Vol. 110, No. 6. pp. 808-817.
@article{a59b43571bc24601a1ab7a80ded7ee97,
title = "Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo",
abstract = "Rationale: Hyperhomocysteinemia is a risk factor of atherogenesis. Soluble epoxide hydrolase (sEH) is a major enzyme that hydrolyzes epoxyeicosatrienoic acids and attenuates their cardiovascular protective effects. Whether homocysteine (Hcy) regulates sEH and the underlying mechanism remains elusive. Objective: To elucidate the mechanism by which Hcy regulates sEH expression and endothelial activation in vitro and in vivo. Methods and Results: Hcy treatment in cultured human endothelial cells dose-dependently and time-dependently upregulated sEH mRNA and protein. Hcy increased the expression of adhesion molecules, which was markedly reversed by inhibiting sEH activity. Hcy-induced sEH upregulation is associated with activation of activating transcription factor-6 (ATF6). Bioinformatics analysis revealed a putative ATF6-binding motif in the promoter region of the sEH gene, which was found at a methylation site. Site-directed mutagenesis and chromatin immunoprecipitation assays demonstrated that Hcy treatment or ATF6 overexpression promoted ATF6 binding to the promoter of sEH and increased its activity. Results of methylation-specific polymerase chain reaction revealed that the ATF6 binding site on the sEH promoter was partially methylated and was demethylated with Hcy. SiRNA knockdown of ATF6α or SP1 blocked and ATF6 overexpression and DNA methyltransferase inhibitor mimicked the effect of homocysteine on sEH upregulation. In vivo, immunofluorescence assay revealed elevated expression of sEH and adhesion molecules in the aortic intima of mice with mild hyperhomocysteinemia, which was attenuated by sEH deletion or inhibition. Conclusion: ATF6 activation and DNA demethylation may coordinately contribute to Hcy-induced sEH expression and endothelial activation. Inhibition of sEH may be a therapeutic approach for treating Hcy-induced cardiovascular diseases.",
keywords = "activating transcription factor 6, demethylation, endothelial cells, homocysteine, soluble epoxide hydrolase",
author = "Donghong Zhang and Xina Xie and Yequn Chen and Hammock, {Bruce D.} and Wei Kong and Yi Zhu",
year = "2012",
month = "3",
day = "16",
doi = "10.1161/CIRCRESAHA.111.259325",
language = "English (US)",
volume = "110",
pages = "808--817",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo

AU - Zhang, Donghong

AU - Xie, Xina

AU - Chen, Yequn

AU - Hammock, Bruce D.

AU - Kong, Wei

AU - Zhu, Yi

PY - 2012/3/16

Y1 - 2012/3/16

N2 - Rationale: Hyperhomocysteinemia is a risk factor of atherogenesis. Soluble epoxide hydrolase (sEH) is a major enzyme that hydrolyzes epoxyeicosatrienoic acids and attenuates their cardiovascular protective effects. Whether homocysteine (Hcy) regulates sEH and the underlying mechanism remains elusive. Objective: To elucidate the mechanism by which Hcy regulates sEH expression and endothelial activation in vitro and in vivo. Methods and Results: Hcy treatment in cultured human endothelial cells dose-dependently and time-dependently upregulated sEH mRNA and protein. Hcy increased the expression of adhesion molecules, which was markedly reversed by inhibiting sEH activity. Hcy-induced sEH upregulation is associated with activation of activating transcription factor-6 (ATF6). Bioinformatics analysis revealed a putative ATF6-binding motif in the promoter region of the sEH gene, which was found at a methylation site. Site-directed mutagenesis and chromatin immunoprecipitation assays demonstrated that Hcy treatment or ATF6 overexpression promoted ATF6 binding to the promoter of sEH and increased its activity. Results of methylation-specific polymerase chain reaction revealed that the ATF6 binding site on the sEH promoter was partially methylated and was demethylated with Hcy. SiRNA knockdown of ATF6α or SP1 blocked and ATF6 overexpression and DNA methyltransferase inhibitor mimicked the effect of homocysteine on sEH upregulation. In vivo, immunofluorescence assay revealed elevated expression of sEH and adhesion molecules in the aortic intima of mice with mild hyperhomocysteinemia, which was attenuated by sEH deletion or inhibition. Conclusion: ATF6 activation and DNA demethylation may coordinately contribute to Hcy-induced sEH expression and endothelial activation. Inhibition of sEH may be a therapeutic approach for treating Hcy-induced cardiovascular diseases.

AB - Rationale: Hyperhomocysteinemia is a risk factor of atherogenesis. Soluble epoxide hydrolase (sEH) is a major enzyme that hydrolyzes epoxyeicosatrienoic acids and attenuates their cardiovascular protective effects. Whether homocysteine (Hcy) regulates sEH and the underlying mechanism remains elusive. Objective: To elucidate the mechanism by which Hcy regulates sEH expression and endothelial activation in vitro and in vivo. Methods and Results: Hcy treatment in cultured human endothelial cells dose-dependently and time-dependently upregulated sEH mRNA and protein. Hcy increased the expression of adhesion molecules, which was markedly reversed by inhibiting sEH activity. Hcy-induced sEH upregulation is associated with activation of activating transcription factor-6 (ATF6). Bioinformatics analysis revealed a putative ATF6-binding motif in the promoter region of the sEH gene, which was found at a methylation site. Site-directed mutagenesis and chromatin immunoprecipitation assays demonstrated that Hcy treatment or ATF6 overexpression promoted ATF6 binding to the promoter of sEH and increased its activity. Results of methylation-specific polymerase chain reaction revealed that the ATF6 binding site on the sEH promoter was partially methylated and was demethylated with Hcy. SiRNA knockdown of ATF6α or SP1 blocked and ATF6 overexpression and DNA methyltransferase inhibitor mimicked the effect of homocysteine on sEH upregulation. In vivo, immunofluorescence assay revealed elevated expression of sEH and adhesion molecules in the aortic intima of mice with mild hyperhomocysteinemia, which was attenuated by sEH deletion or inhibition. Conclusion: ATF6 activation and DNA demethylation may coordinately contribute to Hcy-induced sEH expression and endothelial activation. Inhibition of sEH may be a therapeutic approach for treating Hcy-induced cardiovascular diseases.

KW - activating transcription factor 6

KW - demethylation

KW - endothelial cells

KW - homocysteine

KW - soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84862817897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862817897&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.111.259325

DO - 10.1161/CIRCRESAHA.111.259325

M3 - Article

VL - 110

SP - 808

EP - 817

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 6

ER -